Kura Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-216.88	-173.98	-152.63	-135.84	-130.47	-89.63
Depreciation & Amortization	0.83	0.85	0.85	0.76	0.56	0.19
Stock-Based Compensation	34.39	33.9	28.08	26.32	23.58	12.81
Other Adjustments	-9.44	-12.62	-8.94	1.68	5	0.41
Change in Receivables	-33.88	-	-	-	-	-
Changes in Accounts Payable	27.52	15.2	10.33	-0.8	-2.52	5.68
Changes in Unearned Revenue	317.61	278.18	-	-	-	-
Changes in Other Operating Activities	-32.34	-7.21	-2.51	-2.18	-0.71	0.71
Operating Cash Flow	87.8	134.32	-124.82	-110.06	-104.55	-69.83
Capital Expenditures	-4.69	-0.47	-0.17	-0.63	-1.15	-2.17
Purchases of Investments	-762.4	-659.05	-409.82	-270.66	-445.66	-320.96
Proceeds from Sale of Investments	723.63	557.93	425.55	303.91	319.97	223.2
Investing Cash Flow	-43.46	-101.59	15.56	32.63	-126.84	-99.94
Long-Term Debt Issued	-	-	-	10	-	-
Long-Term Debt Repaid	-	-	-	-	-7.25	-0.25
Net Long-Term Debt Issued (Repaid)	-	-	-	10	-7.25	-0.25
Issuance of Common Stock	1.46	154.42	94.78	29.14	4.43	469.58
Net Common Stock Issued (Repurchased)	1.46	154.42	94.78	29.14	4.43	469.58
Other Financing Activities	-	-	-	-0.58	-0.61	-
Financing Cash Flow	1.46	154.42	94.78	38.57	-3.44	469.33
Net Cash Flow	45.81	187.14	-14.48	-38.87	-234.82	299.57
Free Cash Flow	83.11	133.85	-124.99	-110.69	-105.7	-72
Free Cash Flow Growth	-37.91%	-	-	-	-	-
FCF Margin	79.89%	248.40%	-	-	-	-
Free Cash Flow Per Share	0.95	1.55	-1.71	-1.65	-1.59	-1.36
Levered Free Cash Flow	92.04	112.57	-144.13	-128.69	-141.53	-85.47
Unlevered Free Cash Flow	66.6	91.09	-157.3	-142.71	-135.07	-87.49

Updated Nov 4, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q